Preliminary data show Biotron Ltd.’s lead compound BIT-225 met the primary objectives of the phase II BIT225-011 trial, a longitudinal, open-label trial designed to characterize the effect of the compound added to ongoing, suppressive antiretroviral therapy in HIV-1-infected, treatment-experienced patients who achieved only partial immune reconstitution.
Preliminary data show Biotron Ltd.’s lead compound BIT-225 met the primary objectives of the phase II BIT225-011 trial, a longitudinal, open-label trial designed to characterize the effect of the compound added to ongoing, suppressive antiretroviral therapy in HIV-1-infected, treatment-experienced patients who achieved only partial immune reconstitution.
Novel HIV-1 vaccine strategies should elicit potent and broad immunity against the viral envelope (Env) glycoprotein. Particle presentation of Env has shown promise in animal studies, but has several problems that limit their clinical application.
Gilead Sciences Inc. has patented 4'-Thionucleoside analogues acting as viral replication inhibitors reported to be useful for the treatment of HIV infection.
The autophagy process, a critical regulator of T-cell function, has been shown to control acute HIV-1 infection and play a crucial role also in HIV-1 disease pathogenesis.
For the treatment of HIV infection, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are used to prevent viral replication by binding to a pocket near the polymerase active site of HIV-1 reverse transcriptase.
On March 4, 2024, several groups of scientists discussed the challenges of investigating the effects of HIV in the central nervous system (CNS) at the oral abstract session on neuropathogenesis of HIV held during the 31st Conference on Retroviruses and Opportunistic Infections (CROI), in Denver. A cure for HIV will require eliminating the virus in all its reservoirs, those tissues where HIV remains latent but retains the capacity for reactivation and replication. However, despite antiretroviral therapy (ART), the virus could continue to replicate continuously at a low level in some reservoirs, including the CNS.
Researchers from National Institute of Allergy and Infectious Diseases and affiliated organizations presented data from a study that aimed to assess the protective efficacy of the human fusion peptide (FP) broadly neutralizing antibody (bNAb), VRC34.01, along with two FP vaccine-elicited rhesus macaque mAbs, DFPH-a.15 and DF1W-a.01, to protect naïve rhesus macaques against mucosal challenge with SHIV(BG505).
Researchers at Centre Hospitalier de Université de Montréal and University of Pennsylvania have identified compounds reported to be useful for the treatment of HIV-1 infection.
Researchers from Shandong University and colleagues presented the characterization of [I] as the most active compound from a series of novel diarypyridimine derivatives intended to overcome resistance to NNRTI-resistant HIV-1 strains. The compound displayed EC50 values of 0.0010 and 0.18 µM against HIV IIIB and RES056 strains, respectively.
